Regeneron Pharmaceuticals Inc. v Kymab Ltd
| Jurisdiction | England & Wales |
| Court | Supreme Court |
| Neutral Citation | [2020] UKSC 27 |
| Year | 2020 |
Get this document and AI-powered insights with a free trial of vLex and Vincent AI
Get Started for FreeStart Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your Free Trial
17 cases
-
Illumina Cambridge Ltd v Latvia MGI Tech Sia
...infringe claim 12 of EP 578 (claim set A) by equivalence? 12. [ Miscellaneous issue in relation to s71 Patents Act 1977] MGI Regeneron v Kymab [2020] UKSC 27. 11 In terms of infringement, MGI has various systems alleged to infringe. One system is called StandardMPS and the other is called ......
-
Sandoz AG v Biogen Ma Inc.
...product was within the claim. Breadth of claim insufficiency 323 The Supreme Court considered breadth of claim insufficiency in Regeneron v Kymab [2020] UKSC 27 in the context of a product claim, setting out general principles in paragraph 56 of that judgment. Those principles were consider......
-
Gilead Sciences Inc. (a company registered in the US State of Delaware) v Nucana Plc
...without undue burden, otherwise the claim would not be enabled across its scope. This was not really in dispute (Gilead cited Regeneron v Kymab [2020] UKSC 27 for the same point); NuCana did not, for example, say that the 2MU2FD intermediates related only to a de minimis or irrelevant part ......
-
DSM IP Assets B.v v. Algal Omega 3 Ltd
...[2021] EWCA Civ 1279, [2022] RPC 7 at [51]–[97]. DSM's contentions 546 DSM were critical of Mara for not having cited Regeneron v Kymab [2020] UKSC 27, [2020] RPC 22 and in particular Lord Briggs' summary of the principles at [56], and drew attention to the pertinent sub-paragraphs. DSM con......
Get Started for Free
1 firm's commentaries
-
Case Analysis: Sandoz And Teva v Bristol Myers Squibb ' Court Of Appeal
...is not the first time that a pharma company has been shown to have jumped the gun, or gone too broad in their claims: Regeneron v Kymab [2020] UKSC 27 is a case in point. Nevertheless, the cost benefit analysis, taking such risks into account, most likely still points to early filing: the o......
1 books & journal articles
-
THE DEATH OF THE GENUS CLAIM.
...& III.B.2.b. (436.) This new full-scope doctrine has been exported to United Kingdom law. See Regeneron Pharms. Inc. v. Kymab Ltd. [2020] UKSC 27 [56] (holding that "[e]nablement across the scope of a product claim is not established merely by showing that all products within the releva......